Hormone Evaluation in Artificial Reproductive Technology

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation.

Outcome will be measured as pregnancy success, live born babies and unwanted side effects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lund University
• Collaborator: Ferring Pharmaceuticals
• Treatments: Follicle Stimulating Hormone; Menotropins

Criteria

Inclusion Criteria:

• Normal ovulatory cycles 26-32 days

• First and second IVF treatment

• Indication for IVF is male factor, tubal factor or unexplained infertility

• Medical indication for IVF; >12 months unprotected intercourse

Exclusion Criteria:

• Anti Müllerian Hormone <5pmol or cycle day 2-3 FSH >12

• Endometriosis

• polycystic ovarian syndrome

• pre ovarian failure

• smoking

• male age more than 56.